Elani Bowers Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Abstracts this author is presenting:

• Neoadjuvant and Adjuvant Pembrolizumab plus standard of care (SOC) for the treatment of resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): phase 3 KEYNOTE-689 — Poster session 2
• LEAP-009: Phase 2 study of Lenvatinib with or without Pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 Inhibition) — Poster session 1
• Phase 3 study of Pembrolizumab as adjuvant treatment in high-risk locally advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC) — Poster session 2